PolarSeal®, a pioneering force in advanced manufacturing, proudly announces its participation in the highly anticipated MD&M West 2024, a premier event for medical design and manufacturing. This timely move follows the recent declaration of PolarSeal®'s ambitions to establish a manufacturing arm in the USA.

SURREY, U.K., January 25, 2024 (Newswire.com) - The MD&M West 2024 show, scheduled to take place in February, will serve as a dynamic platform for PolarSeal® to unveil its latest innovations and cutting-edge technologies that push the boundaries of excellence in the medical and manufacturing sectors.

Breaking ground at MD&M West 2024: What to expect from PolarSeal®

PolarSeal® is set to captivate audiences with a showcase of revolutionary medical converting services and advancements poised to redefine industry standards. As a company committed to staying at the forefront of technological evolution, PolarSeal®'s participation in MD&M West underscores its dedication to driving innovation and embracing opportunities for global expansion.

Key Highlights:

1. Service solutions for medical devices: Explore PolarSeal®'s innovative converting solutions, exemplifying the company’s commitment to revolutionizing medical manufacturing standards.
2. Showcasing real-world impact: Witness the transformative outcomes of PolarSeal®'s cutting-edge processes and discover first-hand the practical applications that redefine possibilities in medical manufacturing.
3. Strategic networking: PolarSeal® is eager to connect with industry professionals and potential partners during MD&M West 2024. For collaboration and networking opportunities, engage in meaningful discussions with PolarSeal® representatives at Booth #449.

A vision aligned with excellence: PolarSeal®'s commitment to the future

As PolarSeal® steps onto the global stage at MD&M West 2024, the company reaffirms its commitment to shaping the future of medical design and manufacturing. The company’s attendance at this event is a testament to PolarSeal®'s dedication to excellence, quality, and continued growth in the ever-evolving landscape of advanced manufacturing.

PolarSeal® invites members of the press, industry leaders, and event attendees to visit their booth at Hall A-E Booth #499 at MD&M West 2024. Discover the future of medical manufacturing and explore how PolarSeal® is revolutionizing the industry.

About PolarSeal®

PolarSeal® is a leading name in contract manufacturing, specializing in flexible medical converting. With a global vision and commitment to innovation, PolarSeal® continues to redefine industry standards, creating a lasting impact on the world of medical design and manufacturing.

For more information about PolarSeal®, visit the company's website at https://polarsealmedical.com

Contact Information:
Shaun Kemp
Marketing Manager
[email protected]
+1 (551) 252 4467


Original Source: PolarSeal® Joins Industry Pioneers at MD&M West 2024 for a Showcase of Excellence

Revolutionizing remote healthcare with Ambient AI

PALO ALTO, Calif., January 25, 2024 (Newswire.com) - Caspar.AI, an innovator in AI-driven remote healthcare technology, today announced the worldwide launch of its Contactless Vitals & Real-Time Bed Monitoring Solutions. Leveraging 150 billion data points about home behaviors, Caspar.AI's patient-centric models enable remote healthcare providers to extend their services effectively into both facilities and home environments.

Revolutionizing Remote Healthcare
The Journal of Clinical Nursing (March 12, 2018) highlights a conflict of care: balancing patients’ sleep with vital sign checks. This challenge is more pronounced for home-based patients, where remote healthcare providers may miss critical health insights. Caspar.AI's solution offers non-intrusive monitoring of heart rate and respiration rate during sleep, prioritizing patient privacy, health, and comfort.

Groundbreaking Technology: GPTs and LLMs for Comprehensive Health Monitoring
Caspar.AI employs proprietary Generative Pre-trained Transformers (GPTs) for 3D multi-modal data and LLMs trained on medical records. This innovative approach combines contactless radar and WiFi-based sensing technologies for all-around monitoring of vital signs and 3D movements. It cross-correlates data from medical records to detect medication side effects and provides interpretable, evidence-based analytics for a variety of health concerns, including cardiac & respiratory issues, sleep quality & scores, and movement-related conditions.

Patient-Centric AI for Effective and Efficient Care
Trained on over 150 billion data points, Caspar.AI's models cater to diverse patient profiles, aiding both remote and onsite staff in identifying critical health conditions efficiently. The patient-adaptive GPT reduces alert fatigue by customizing alerts to each patient's unique vital sign baseline, accommodating variations like an athlete's lower resting heart rate compared to an elderly individual's higher rate.

Proactive Real-Time Alerts for Enhanced Safety
In facility environments, unsupervised bed exits are a leading cause of injuries. Caspar.AI's solution proactively issues alerts by tracking 3D movements and vital sign changes. This facilitates rapid detection of critical situations, including unsupervised bed exits, prolonged inactivity, and specific cardiac or respiratory conditions. The solution also detects risks related to pressure ulcers, sleep apnea, joint issues, and medication or sleep disturbances, enabling timely intervention. Caspar.AI alerts integrate seamlessly into existing operational workflows, including remote care platforms and nurse call systems.

Improved Patient Care and Remote Care Reimbursements
Communities like Arcadia, Shellpoint, and Melur Meadows have implemented Caspar.AI's technology, enhancing patient care and optimizing operational efficiency. The Caspar.AI solution not only improves care quality but also facilitates higher insurance reimbursements through various CPT codes, potentially up to $150 per patient per month.

"Technology innovation is key to providing exceptional care and keeping residents safe. Caspar.AI's contactless vitals and bed-monitoring help us prevent unanticipated bed exits and offer valuable insights to our care team," said Brian Hinds, Chief Information Officer at Shell Point Retirement Community.

For Further Information
Visit https://caspar.ai/ or contact us at [email protected].

Contact Information:
Ryan Humphreys
[email protected]


Original Source: Caspar.AI Launches Contactless Vitals & Real-time Bed Monitoring Solutions with Arcadia, Shellpoint, and Melur Meadows

Completion of Recent Funding Round Allows Alopex to Expand Staff and Enhance Technology

LAS VEGAS, January 25, 2024 (Newswire.com) - Shifox, the provider of complex care management services and technology, has rebranded under the name Alopex powered by Shifox.

Shifox, founded in 2014 as a pioneer in healthcare innovation, proudly unveils its transformation into Alopex. The company was created to enable care coordination and support the achievement of quality outcomes through its advanced technology platform and the rebrand centers around the addition of a full suite of clinical service options and care management programs.

Derived from the ancient Greek word for "Fox," the new Alopex brand evokes the fox’s qualities of adaptability, intelligence, and resourcefulness. The Company is dedicated to embodying these traits in its mission to humanize healthcare by offering Provider-Connected, Patient-Centered, and Personally Coordinated Solutions.

Alopex integrates crucial components that will transform how care for patients with chronic conditions is delivered: trusted, comprehensive technology solutions and professional personal care planning and transitional care coordination on behalf of providers nationwide.

By 2030, an estimated 171 million people will grapple with chronic diseases and social determinants of needs challenges. This challenge encompasses some of the most common, costly, and preventable health issues, such as Heart Disease, Diabetes, COPD, Hypertension, Nephropathy, and Obesity. The Alopex suite of services is tailored specifically for care coordination and management of these conditions, and the Company’s objective is to empower patients to flourish despite the complexities and frustrations of the healthcare system.

Jeffery Topfer, the Company’s founder, president, and CEO, said, “Our goal has always been to enable comprehensive patient cohorts to thrive in a fragmented healthcare ecosystem. Our rebranding conveys our commitment to the idea that the comprehensive care desired by patients and providers alike is achievable.”

The Company also announced the completion of a funding round led by TLI Bedrock, LLC. Alopex will use the proceeds to expand its staff and for further technology enhancements to serve its customers.

About Alopex:

Our mission is to provide innovative, flexible care management technology coupled with personalized, preventative care planning and coordination to healthcare organizations. To learn more, visit our website at Alopexcare.com or contact us directly at 866-744-3691.

About TLI Bedrock:

TLI Bedrock is a multi-strategy fund that invests across sectors and industries. It seeks high returns by backing innovative projects, responsible companies that think broadly about customer, employee and community needs, and sustainable approaches to commerce. "TLI" stands for trust, loyalty, and integrity. Its website is TLIBedrock.com.

Contact Information:
Sean Ballance
Vice President Sales and Marketing
[email protected]
5613506780
Related Files
Care Managment One Page SB.pdf



Original Source: Shifox Re-Brands as Alopex and Announces Completion of Investment Round

CHICAGO, January 22, 2024 (Newswire.com) - The American Society for Transplantation and Cellular Therapy (ASTCT), the Association of American Cancer Institutes (AACI), and the Association of Community Cancer Centers (ACCC) recently announced the RECUR initiative. The initiative is a collaboration among these organizations, aimed at revolutionizing the evaluation process for CAR T therapy, focusing on five crucial factors to ensure timely and personalized care.

CAR T therapy has demonstrated remarkable potential in the treatment of relapsed/refractory large B-cell lymphoma (LBCL), offering new, more effective therapy to patients with relapsed disease, some who have already exhausted traditional treatment options. However, identifying eligible candidates and facilitating access to CAR T therapy necessitates an awareness of several key considerations by referring oncologists, including:

1. Relapsed/Refractory LBCL: Most patients with relapsed or refractory LBCL can be considered for CAR T cell therapy. Recognizing the patient's medical history and examining their response to previous treatments plays a pivotal role in determining their eligibility.

2. Every Age and Comorbidity: Age and existing medical conditions should not hinder patients from accessing potentially curative CAR T therapy. The RECUR initiative emphasizes personalized care for patients of all ages and backgrounds.

3. Caregiver Support: Acknowledging the vital role of caregivers and the necessary support systems is essential. Their involvement significantly impacts a patient's treatment and wellbeing.

4. Urgency to Refer the Patient for Consult: Identifying the urgency to refer patients for CAR-T cell consultation ensures timely access to life-saving therapies, providing patients with the best opportunity for a positive outcome.

5. Receive Patients Returning Post-CAR T Therapy: Recognizing the potential need for follow-up care after CAR T therapy is vital. Ensuring appropriate infrastructure and support for these patients after their cell therapy allows for seamless continuity of care.

Through the RECUR initiative, ASTCT, AACI, and AACC aim to empower oncologists, healthcare professionals, and patients alike with an understanding of the factors necessary for successful CAR T therapy, and the importance of early and timely referral for consultation with a center with expertise. By streamlining the efficiency of the referral process and fostering collaboration among medical experts, this initiative seeks to enhance patient outcomes and expand access to life-saving treatments.

Peter Riedell, MD, chair of AACI's CAR T Initiative Steering Committee, expressed his commitment to the initiative, stating, "The launch of RECUR marks an important milestone in advancing personalized care for cancer patients. By focusing on these key factors and promoting collaboration, we can optimize and achieve equal access to the delivery of CAR T therapy to those who need it most, regardless of age, comorbidities, or previous treatment history."

In collaboration with leading experts in the field, the RECUR initiative is set to host educational programs, provide resources, and create a platform for knowledge exchange to support healthcare professionals and patients in navigating the complexities of CAR T therapy.

For more information about the RECUR initiative and its endeavors, please visit https://www.astctjournal.org/article/S2666-6367(23)01642-1/fulltext.

###

About ASTCT:

The American Society for Transplantation and Cellular Therapy (ASTCT) is an international professional society dedicated to improving the lives of blood and marrow transplant and cellular therapy patients. ASTCT represents more than 3,900 physicians, investigators, and other health care professionals from more than 45 countries. Our mission is dedicated to improving the application and success of blood and marrow transplantation and related cellular therapies. We strive to be the leading organization promoting research, education, and clinical practice in the field. For more information about ASTCT, visit www.astct.org.

About AACI:

The Association of American Cancer Institutes (AACI) represents over 100 premier academic and freestanding cancer centers in the United States and Canada. AACI is accelerating progress against cancer by enhancing the impact of academic cancer centers and promoting cancer health equity. For more information about AACI, visit www.aaci-cancer.org.

About ACCC:

The Association of Community Cancer Centers (ACCC) is a powerful community of more than 34,000 multidisciplinary practitioners and 1,700 cancer programs and practices nationwide. Founded in 1974, ACCC brings together healthcare professionals across all disciplines in oncology to promote quality cancer care. It is estimated that 65 percent of the nation's cancer patients are treated by a member of ACCC. For more information about ACCC, visit www.accc-cancer.org.

Contact Information:
Jennifer Kasowicz
ASTCT Marketing Director
[email protected]
(312) 673-4970


Original Source: ASTCT, AACI, and ACCC Launch RECUR Initiative to Enhance Patient Access to CAR T Therapy

Free webinar on ketamine therapy - Mon, Feb 5, 2024, 6PM PST

PALM SPRINGS, Calif., January 22, 2024 (Newswire.com) - Join us on Monday, February 5, 2024, at 6 PM Pacific Time for an enlightening webinar that delves into the transformative role of ketamine in modern healthcare. Titled "The Ketamine Story: Transforming Treatment for Mood Disorders and Pain," this event promises to be an insightful discussion in the evolving field of transformative medical care.

Expert Panelists Shed Light on Ketamine Therapy

This free webinar will feature a panel of distinguished experts, including Dr. Glareh Imani, DO a board-certified emergency medicine physician with a rich academic background & founder of Nameen Infusion & Wellness; Dr. Ray Rivas, MD, founder of Innerbloom Ketamine Therapy, who brings a unique perspective shaped by his journey from trauma surgery to mental health care; and Dr. Sam Ko, MD, a leading figure in ketamine therapy, known for his holistic approach at Reset Ketamine.

Exploring the Past, Present, and Future of Ketamine

Our 3 panelists will explore the evolution of ketamine from a general anesthetic to its current status as a breakthrough treatment for mood disorders and pain conditions. This 60-minute webinar, including a 25-minute Q&A session, is designed to provide a comprehensive overview of ketamine therapy, covering its historical context, current applications, and future potential.

Who Should Attend?

This webinar is essential for individuals curious about ketamine therapy, whether they are considering treatment or simply seeking to expand their knowledge. It caters to a wide audience with varying levels of understanding of this transformative treatment.

Easy Registration and Technical Details

Register for this insightful webinar today. For this Zoom hosted webinar, attendees do not need their own Zoom account to attend. Join through a browser or the Zoom app from any desktop, laptop, mobile device. 

Register for this webinar here: https://us06web.zoom.us/webinar/register/3417058996077/WN_kYC4KorOQ3G_DGE-5TO6Cg 

Contact Information for Further Inquiries

For any questions or further information, please reach out to us at:

• [email protected] (Dr. Sam Ko) www.resetketamine.com
• [email protected] (Dr. Glareh Imani) www.nameeninfusion.com
• [email protected] (Dr. Ray Rivas) www.innerbloomketamine.com

Why This Webinar is a Must-Attend

Our webinar stands out due to the unique blend of expertise and passion our speakers bring to the table. These specialists are not just advocates of ketamine therapy; they are actively involved in patient care, utilizing their extensive medical training to provide the highest level of treatment. This session is an opportunity to hear from those who practice what they preach in the field of transformative care.

A Message from Our Speakers

"What the audience will gain from this webinar is a comprehensive understanding of ketamine therapy's journey: its historical roots, current practices, and a glimpse into its exciting future. Knowledge is the key to dispelling any myths and fears around this innovative treatment." 

Join us for a session that promises to be as informative as it is transformative: https://us06web.zoom.us/webinar/register/3417058996077/WN_kYC4KorOQ3G_DGE-5TO6Cg

Contact Information:
Glareh Imani
Founder
[email protected]
(602) 598-1398

Ray Rivas
Founder
[email protected]
(805) 321-8471

Sam Ko, MD
CEO
[email protected]
(760) 422-5578


Original Source: The Ketamine Story: Transforming Treatment for Mood Disorders and Pain

Presentations at long-running, prestigious meeting will focus on effectiveness of sustained acoustic medicine in soft tissue healing.

TRUMBULL, Conn., January 22, 2024 (Newswire.com) - ZetrOZ Systems, makers of the sam® wearable ultrasound unit, is at the 26th annual Big Sky Sports Medicine Conference, Jan. 21-25, 2024, at Big Sky Resort, Montana, presenting technologies including the sam® long-duration sustained acoustic medicine device for accelerating soft tissue injury healing.  

At the conference, ZetrOZ Systems will showcase its sam X1 (wireless device) and sam 2.0 devices. It hosted Sunday’s welcome reception, “DJ/Enovis withSamSport NFL Playoffs Welcome Reception, Brian Moore, and George Lewis Hosts,” at 6:00 p.m. in the Jefferson Room and is presenting its technology at tables 27 and 28 in the exhibit hall. 

What began as an opportunity for sports medicine caregivers to discuss current issues in an engaging environment has grown into a multi-disciplinary sports medicine conference. The BSSMC, a multidisciplinary gathering of leading sports medicine professionals, will feature educational sessions and workshop presentations on original research, especially in concussions. The conference will also host a talk by distinguished guests Dr. Jeffrey Kutcher, a renowned sports neurologist and director of the Kutcher Clinics, and Dr. Geoffrey Baer from the University of Wisconsin.  

Two of the presentations will focus on soft tissue injury and healing, including from George K. Lewis, the founder and CEO of ZetrOZ Systems and a biomedical engineer: 

“Regenerative Medicine Applications in Sports Medicine for Soft Tissue Healing and Return to Play” by Jason Krystofiak, MD, CAQSM, Medical Director of Sports Medicine, RWJBarnabas Health, Rutgers Football Team Physician 

“Clinical Effectiveness of Sustained Acoustic Medicine in the Treatment of Soft Tissue Injury” George K. Lewis, PhD, MS., Biomedical Engineer, Mechanobiologist and Neurobiologist in Regenerative and Sports Medicine  

“The Big Sky Sports Medicine Conference is an ideal platform for ZetrOZ Systems' breakthrough sustained acoustic medicine products,” Lewis said. “For treating professional athletes, our sam® 2.0 and X1 ultrasound devices are clinically proven to accelerate soft tissue healing and relieve pain without invasive procedures.” 

“We look forward to being part of the Big Sky Sports Medicine Conference and the opportunity to demonstrate our technology to sports medicine professionals and see how our sam® devices can treat soft tissue injuries,” Lewis added.  

Developed from research funded by the National Institute of Health and the US Department of Defense, the sam® X1 and sam® 2.0 devices are drug-free, non-invasive, and a ground-breaking solution for pain management and accelerated soft tissue healing.  

The devices use low-intensity, long-duration, daily ultrasound treatment that can reduce the need for pain medication and surgery and provide more rapid healing and reduced pain. Utilizing mechanobiological technology, the treatment works by increasing blood vessel diameters to improve blood flow, increase oxygenated hemoglobin and remove cytokine enzymes and cellular waste.  

Cleared by the U.S. Food and Drug Administration for expanded indications to treat soft tissue injuries and knee osteoarthritis, the sam® device will now be available to patients with a wide range of medical conditions. It is the most sought-after regenerative ultrasound technology for soft tissue injuries and joint arthritis, clinically validated in over 40 studies with over 3.7 million treatments delivered in the United States. 

“Now, the sam® wearable ultrasound unit has been FDA-cleared for expanded medical indications,” Lewis said. “This will make it easier for doctors and their patients to utilize our ultrasound treatment to speed injury healing without the need for oral medication, corticosteroids, or surgery.” 

For more information on ZetrOZ Systems, please visit www.samrecover.com.  

About ZetrOZ Systems  
ZetrOZ Systems is leading healing innovations in sports medicine, developing wearable bioelectronic devices to deliver sustained acoustic medicine (sam®). Researched and funded by the federal government, ZetrOZ is built on the proprietary medical technology of 46 patents and is the exclusive manufacturer and developer of the sam® product line designed to treat acute and chronic musculoskeletal conditions. 

Contact Information:
Maria Penaloza
[email protected]
Related Images


Original Source: ZetrOZ Systems to Showcase sam® Ultrasound Treatment Technology at the 2024 Big Sky Sports Medicine Conference